The External Quality Assessment Scheme (EQAS) evaluates the performance of participating laboratories through an external agency by which known blinded samples are sent to participants for analysis, and their performance evaluated and monitored.
INTRODUCTION
The quality management system model developed by the Clinical and Laboratory Standards Institute (CLSI), lists assessment an important element of the 12 quality system essentials and defines it as a tool for examining laboratory performance and comparing it to standards, benchmarks or the performance of other laboratories. 1 An external quality assessment scheme (EQAS) is a method by which an independent external agency uses known samples with undisclosed results and is commonly used to establish inter-laboratory comparability. 2 In the Philippines, participation in an external quality assessment scheme for transfusion transmissible infections is a mandatory requirement for the licensure of blood service facilities 3 and aims to raise the standards on the quality testing of blood units.
This activity evaluated the performance of the blood service facilities in the Philippines by analyzing the results of the external quality assessment scheme conducted by the Transfusion Transmissible Infections -National Reference Laboratory in 2017.
METHODOLOGY

Panel Composition
The TTI EQAS 2017 test event consisted of two panels, the HVHT4120 for blood donor serology, and the MLRA415 for malaria slide microscopy. The HVHT4120 consisted of twenty (20) pooled plasma samples obtained from blood donors from different regions of the country. Each pooled sample was prepared by mixing similar volumes of at least two samples that had similar antibody and antigen profiles. All samples were subjected to filtration prior to aliquoting. The samples were aliquoted, and their homogeneity confirmed. The serology profile for HIV, HBV, HCV, Syphilis of each sample were identified using a chemiluminescence assay (ChLIA), enzyme immunoassay (EIA), Rapid Plasma Reagin (RPR), Particle Agglutination (PA) and a Differentiation/Supplemental Assay (SA).
Program code MLRA415 consists of five (5) 
Participants
The multimarker blood serology EQAS panel ID HVHT4120 and malaria microscopy EQAS panel ID MLRA415 were distributed to 180 participants nationwide. These participants enrolled for the EQAS 2016 test event with a corresponding registration fee to cover expenses for the test event.
Majority of the participants were private institutions (44%) followed closely by government institutions (42%) and the remainder are from the different Philippine Red Cross chapters (14%). Figure 1 shows the distribution of participants by region. 
Data Analysis
RESULTS AND DISCUSSION
A total of 14,392 results were generated from 75 assays for the HVHT4120 panel and 885 results were generated from 1 assay for the MLRA415 panel.
Data entry errors:
Two participants reported a "reactive" test result but submitted a "negative" assay interpretation.
False positive results: Nine participants reported false reactive results on known negative samples.
False negative results:
Five participants reported false negative results on initial testing.
Educational sample (HIV and HCV):
Two participants reported false negative results on the HIV and HCV sample with one of the participants having reported a "reactive" test result but submitted a "negative" assay interpretation. One participant had reported a reactive HBsAg result.
Educational sample (HIV p24 Antigen): Two participants reported a "reactive" result using a 3 rd generation HIV assay. Eleven participants reported a "negative" result using a 4 th generation HIV assay with one participant having reported a "reactive" test result but submitted a "negative" assay interpretation. Three participants reported an "inconclusive" test result using a 4 th generation HIV assay. Three participants reported a reactive HBsAg result on the HIV p24 antigen sample.
Of the total number of results generated in the HVHT4120 panel, 51 results (0.35%) were reported as aberrant.
On rating the performance of the participants, the following criteria must be met to be classified as an unsatisfactory performer in the HVHT4120 initial panel: (a) at least one false negative result; (b) at least twenty percent (20%) false positive results. In accordance with these criteria, corresponding participants were given an investigation checklist to assist them in identifying errors and make the necessary corrective actions and/or troubleshooting methods. A 2nd set of the HVHT4120 panel were given to participants for retesting if the identified unsatisfactory performance was due to a testing error. Participants with aberrant results due to transcription errors were only given an investigation/ troubleshooting checklist and a written recommendation. Three (10) participants were given a second set of samples wherein one participant had reported a false negative result and one participant did not submit their results.
Of the total number of results generated in the MLRA415 panel, 86 results (9.72%) were reported as aberrant. Figure 2 shows the distribution of grades of the participants. 
CONCLUSION
EQAS is an essential element of the quality system and plays a vital role in facilitating optimal patient care. 4 The transfusion transmissible infections EQAS directed for blood service facilities was designed to assess the entire phase of testing and monitor the quality of laboratory results. This also enables the participants to compare their performance with other laboratories and this can aid them in detecting potential problems which present opportunities for improvement.
RECOMMENDATION
The participants should regularly review their results as part of quality improvement regardless of their rating. Participants should take responsibility in implementing the necessary corrective action as part of the quality assurance program in their laboratory.
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In accordance with these criteria, corresponding participants were given an investigation checklist to assist them in identifying errors and make the necessary corrective actions and/or troubleshooting methods. A 2nd set of the HVHT4120 panel were given to participants for retesting if the identified unsatisfactory performance was due to a testing error. Participants with aberrant results due to transcription errors were only given an investigation/troubleshooting checklist and a written recommendation. Three (10) participants were given a second set of samples wherein one participant had reported a false negative result and one participant did not submit their results.
Of the total number of results generated in the MLRA415 panel, 86 results (9.72%) were reported as aberrant. Figure 2 shows the distribution of grades of the participants. They have been evaluated and graded as follows:
 Excellent -100% acceptable results on the initial panel (all final results were correctly identified in comparison with the reference results);  Very Satisfactory -Less than 100% acceptable results on the initial panel without being given a second panel for retesting.  Satisfactory -100% acceptable results on retesting of the second panel; or had an aberrant result in the initial panel due to a clerical error, given that the participant was able to identify this error through the EQAS investigation checklist.  Poor -Participant did not follow minimum requirements of testing as per DOH Circular No.
2013-0132 or less than 100% acceptable results on retesting of the second panel; or had an aberrant result in the initial panel due to a clerical error which the participant had failed to identify in the EQAS investigation checklist. 
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